PPARD and metabolic disease: With in-depth investigation, it has been demonstrated that FGF21 could modulate the activity of proliferator-activated nuclear receptor δ (PPAR-δ), so FGF21 is considered as a crucial PPAR-δ agonist which ameliorates metabolic disorders [85].